Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular dysfunction. A pooled analysis of 10 primary prevention trials

Nanthakumar, Kumaraswamy; Epstein, Andrew E.; Kay, G.N.; Plumb, Vance J.; Lee, D.S.

doi:10.1016/j.accreview.2005.03.037

Cited by 55 publications

(69 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 The survival benefits from ICDs stem from their ability to acutely terminate ventricular arrhythmias (VAs) using high-energy shocks. While shock efficacy remains probabilistic, increased confidence in an ICD's ability to successfully terminate spontaneous VAs can be established with defibrillation threshold (DFT) testing.…”

Section: Introductionmentioning

confidence: 99%

Predictors of Elevated Defibrillation Threshold with the Subcutaneous Implantable Cardioverter-defibrillator

Chang

Konečný

et al. 2017

J Innov Cardiac Rhythm Manage

View full text Add to dashboard Cite

ABSTRACT. There are limited data regarding defibrillation thresholds (DFTs) for the subcutaneous implantable cardioverter-defibrillator (S-ICD), and factors associated with elevated DFTs remain incompletely understood. The objective of this study was to determine the factors associated with elevated DFTs in patients undergoing S-ICD implantation. A retrospective cross-sectional analysis of all patients undergoing S-ICD implantation at our institution between 2013 and 2016 who underwent step-down DFT testing was performed. Factors associated with a higher DFT were analyzed. In total, 56 patients (mean age: 49.3 ± 13.1 years, mean left ventricular ejection rate: 31.1% ± 13.7%) underwent S-ICD implantation in the study period. Full DFT testing was performed in 31 of the 56 patients (55%), with an average DFT of 46.4 joules (J) ± 25.9 J found among this cohort. The DFT was 4 65 J in five of the 31 patients (16%). A high DFT was associated with increased body mass index (BMI) (37.7 kg/m 2 versus 29.4 kg/m 2 ; p ¼ 0.02) and either increased septal or posterior wall thickness (1.5 cm versus 1.0 cm; p ¼ 0.0003 and 1.4 cm versus 1.1 cm; p ¼ 0.003, respectively). Patients with high DFTs also had higher failed shock impedance values (138 O versus 71 O; p ¼ 0.005). Renal failure did not appear to affect DFT (51.4 J versus 51.7 J; p ¼ 0.99). BMI, body surface area (BSA), and septal and posterior left ventricular wall thickness predicted elevated DFT on univariate analysis, although findings were not significant with multivariate analysis due to the small sample size. Thus, elevated S-ICD DFT appears to be associated with increased BMI, BSA, and septal or posterior wall thickness. In contrast, dialysis-dependent renal failure is not associated with elevated DFT. Further investigation is necessary in order to better characterize and predict which patients are at-risk for high DFTs.

show abstract

Section: Introductionmentioning

confidence: 99%

Predictors of Elevated Defibrillation Threshold with the Subcutaneous Implantable Cardioverter-defibrillator

Chang

Konečný

et al. 2017

J Innov Cardiac Rhythm Manage

View full text Add to dashboard Cite

show abstract

“…Il s'agit des études MADIT I [6], CABG-Patch [7], MUSTT [8], MADIT II [9], CAT [10], AMIOVIRT [11], COMPANION [12], DEFINITE [13], SCD-HeFT [14] et DINAMIT [15]. Une récente méta-analyse des dix études randomisées rapporte une réduction relative de 25 % et une réduction absolue de 7,9 % de la mortalité globale pendant un suivi moyen de deux à quatre ans avec le défibrillateur [16]. Quatre de ces études se sont avérées négatives (AMIOVIRT, CAT, CABG, DINAMIT) et les autres ont démontré le bénéfice de la défibrillation.…”

Section: Prévention Primaire De La Mort Subiteunclassified

Le défibrillateur automatique implantable ventriculaire

Heuzey

Aliot

2007

Med Sci (Paris)

View full text Add to dashboard Cite

“…This was not sensitive to removal of the any of the trials from the analysis. The benefit of ICD therapy in sudden cardiac death prevention is above and beyond the mortality benefit associated with use of beta blocker and ACE-I in patients with systolic heart failure (Nanthakumar et al 2004). …”

Section: Primary Prevention Of Scd In Patients With Non-ischemic Cardmentioning

confidence: 99%

Prevention of Sudden Cardiac Death in Patients with Cardiomyopathy

Chekakie¹

2012

Cardiomyopathies - From Basic Research to Clinical Management

View full text Add to dashboard Cite

Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular dysfunction. A pooled analysis of 10 primary prevention trials

Cited by 55 publications

References 0 publications

Predictors of Elevated Defibrillation Threshold with the Subcutaneous Implantable Cardioverter-defibrillator

Predictors of Elevated Defibrillation Threshold with the Subcutaneous Implantable Cardioverter-defibrillator

Le défibrillateur automatique implantable ventriculaire

Prevention of Sudden Cardiac Death in Patients with Cardiomyopathy

Contact Info

Product

Resources

About